Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) major shareholder Ra Capital Management, L.P. sold 376,526 shares of the stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $0.71, for a total transaction of $267,333.46. Following the completion of the sale, the insider owned 418,813 shares in the company, valued at $297,357.23. This represents a 47.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
Ra Capital Management, L.P. also recently made the following trade(s):
- On Tuesday, May 12th, Ra Capital Management, L.P. sold 101,151 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total transaction of $64,736.64.
- On Monday, May 11th, Ra Capital Management, L.P. sold 87,490 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.67, for a total transaction of $58,618.30.
Werewolf Therapeutics Stock Performance
NASDAQ:HOWL traded down $0.03 during trading hours on Tuesday, hitting $0.63. The stock had a trading volume of 500,207 shares, compared to its average volume of 436,209. The business’s 50 day moving average is $0.81 and its 200-day moving average is $0.84. The company has a market cap of $30.71 million, a price-to-earnings ratio of -0.51 and a beta of 0.41. Werewolf Therapeutics, Inc. has a one year low of $0.53 and a one year high of $2.38.
Wall Street Analyst Weigh In
HOWL has been the subject of several recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Monday, April 20th. Wall Street Zen lowered Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Two research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $3.75.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of HOWL. Qube Research & Technologies Ltd acquired a new stake in Werewolf Therapeutics in the 2nd quarter valued at approximately $48,000. Regal Investment Advisors LLC boosted its position in Werewolf Therapeutics by 93.3% during the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after acquiring an additional 25,389 shares during the last quarter. Vontobel Holding Ltd. grew its stake in shares of Werewolf Therapeutics by 66.7% during the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after acquiring an additional 24,003 shares in the last quarter. AQR Capital Management LLC bought a new position in shares of Werewolf Therapeutics during the 1st quarter worth approximately $79,000. Finally, Susquehanna International Group LLP raised its holdings in shares of Werewolf Therapeutics by 16.9% in the third quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock valued at $183,000 after purchasing an additional 13,439 shares during the last quarter. 64.84% of the stock is owned by institutional investors and hedge funds.
About Werewolf Therapeutics
Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.
Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.
Featured Articles
- Five stocks we like better than Werewolf Therapeutics
- Navy Catalyst Ignites Odysight’s Growth Engine
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
- Axon Surged After Earnings and Is Still Down Over 50% From Highs
- The Event That Could Redefine Apple’s Summer Rally
Receive News & Ratings for Werewolf Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Werewolf Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
